[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphangioleiomyomatosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphangioleiomyomatosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,67,97,122,148,169],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":4,"leadSponsor":41,"locationsCount":44},"100054496","study-of-the-disease-process-of-lymphangioleiomyomatosis-100054496",false,"NCT00001465","Study of the Disease Process of Lymphangioleiomyomatosis","Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)","* INCLUSION CRITERIA:\n\nGeneral admission criteria for patients include one or both of the following:\n\nFindings on lung biopsy diagnostic of LAM;\n\nFindings on chest x-ray and\u002For chest computed axial tomography consistent with LAM.\n\nPatients with TSC and pulmonary LAM will be included in the study.\n\nNormal non-smokers in the control group are defined as individuals who have not smoked for greater than or equal to 1 year and have no systemic or pulmonary disease.\n\nNormal smokers defined as individuals with no systemic or pulmonary disease, who have smoked for greater than or equal to 1 year and have normal chest x-ray and normal pulmonary function tests may be included if needed as controls for a similar population of patients with LAM.\n\nPregnant and or nursing women can be included in accordance with Federal Regulations at Subpart B of 45 CFR 46 Subjects who are pregnant and or nursing will be excluded from procedures during their pregnancy that are greater than minimal risk, until they are no longer pregnant and\u002For nursing. Procedures that will not be completed while the subject is pregnant and\u002For nursing including: PFTs, Six Minute Walk Test, thoracentesis, bronchoscopy, and measurements with imaging modalities requiring contrast or with radiation exposure such as Chest x-ray, CT scan, MRI, bone densitometry (DEXA). Allowing subjects to be included in the study may glean important information about individuals with uncommon pulmonary disease during and post pregnancy.\n\nEXCLUSION CRITERIA:\n\nExclusion criteria for patients include:\n\nAge less than 16.\n\nAdvanced stage of a pulmonary or a systemic illness in which the risk of the study is judged to be significant even in the absence of a clear contraindication to the procedures.\n\nExclusion criteria for patients for the formal exercise study and the stress echocardiogram include patients on continuous oxygen. Patients may perform an exercise test that will assess the patient's exercise capacity with activities of daily living.","ALL","16 Years","100 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","Pulmonary lymphangioleiomyomatosis (LAM) is a destructive lung disease typically affecting women of childbearing age. Currently, there is no effective therapy for the disease and the prognosis is poor.\n\nThis study is designed to determine the disease processes involved at the level of cells and molecules, in order to develop more effective therapy.\n\nResearchers intend to identify the proteins and genes that contribute to the process of lung destruction in affected individuals.",[25,26,27,28],"Lung Disease","Pneumothorax","Tuberous Sclerosis","Lymphangioleiomyomatosis",[30,31,32,26,27,33],"Smooth Muscle Proliferation","Bronchoscopy","Female","Natural History","RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":38},"1995-12-18",{"name":42,"class":43},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100491205","tsc-biosample-repository-and-natural-history-database-100491205","NCT05676099","TSC Biosample Repository and Natural History Database","TSC Alliance Tuberous Sclerosis Complex (TSC) Biosample Repository and Natural History Database","Inclusion Criteria:\n\n* Diagnosis of tuberous sclerosis complex or lymphangioleiomyomatosis (sporadic LAM).\n\nExclusion Criteria:\n\n\\-",{"count":53,"type":21},5000,"50 Years","The TSC Biosample Repository collects and stores samples of blood, DNA, and tissues that scientists can request to use in their research. The samples we collect are all linked to clinical data in the TSC Natural History Database. The TSC Natural History Database captures clinical data to document the impact of the disease on a person's health over his or her lifetime. This data may be collected retrospectively or prospectively.",[27,28],"2026-06-19",{"date":37,"type":38},{"date":60,"type":38},"2016-01",{"date":62,"type":21},"2050-12",{"name":64,"class":65},"National Tuberous Sclerosis Association","OTHER",26,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":74,"minAge":75,"maxAge":18,"enrollmentInfo":76,"targetDuration":4,"studyType":78,"phases":79,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":44},"100193865","phase-1-nebulized-or-inhaled-albuterol-for-lymphangioleiomyomatosis-100193865","NCT01799538","Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis","Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With Lymphangioleiomyomatosis","* INCLUSION CRITERIA:\n* Diagnosis of LAM either by tissue biopsy, evidence of lung and other organ involvement (renal angiomyolipomas, chylous effusions, lymphangioleiomyomas), high serum levels of vascular endothelial growth factor D (VGEF-D)(1) or a diagnosis of TSC associated with cystic lung lesions.\n* Age 18 years or over\n* Evidence of airflow obstruction: FEV1\u002FVC ratio \\\u003C fifth percentile of predicted normal and an FEV(1) \\\u003C80% predicted of the normal values.\n\nEXCLUSION CRITERIA:\n\nSubjects will be excluded from the study if they meet one or more of the following criteria:\n\n* History of hypersensitivity to albuterol or any of its components.\n* Moderate or large pleural effusions (chest x-ray and or CT scan procedure completed under Protocol 95-H-0186)\n* History of seizures other than during infancy\n* Inability to withhold bronchodilators for 24 hours\n* Cognitive Impairment\n* Age less than 18 years\n* Male sex\n* Status-post lung or kidney transplantation\n* Pregnant or breast feeding (women of childbearing potential will undergo a blood or urine pregnancy test under Protocol 95-H-0186).\n* Treatment with monoaminoxidase inhibitors, tricyclic antidepressants or Beta-adrenergic receptor antagonists or long acting anticholinergic bronchodilators who are unable to be discontinued for at least seven days before enrollment.\n* Patients with URI, uncontrolled hyperthyroidism or severe gastro-esophageal reflux. Major systemic diseases (i.e., malignancy; myocardial infarction or unstable angina; type 1 diabetes, severe hypertension; liver cirrhosis).","FEMALE","18 Years",{"count":77,"type":21},100,"INTERVENTIONAL",[80,81],"PHASE1","PHASE2","Background:\n\n\\- Lymphangioleiomyomatosis (LAM) is a rare type of lung disease that occurs almost exclusively in women. In LAM, muscle tissue grows in the lungs and starts to block the flow of air. It is a progressive disease, and in severe cases may require a lung transplant. One possible treatment to improve breathing in people with LAM is inhaled albuterol. Albuterol can be given in a metered dose inhaler (MDI) or with a nebulizer. Researchers want to compare these methods to see which method best improves lung function in women with LAM.\n\nObjectives:\n\n\\- To see whether a nebulizer or MDI can better improve lung function in women with LAM.\n\nEligibility:\n\n\\- Women at least 18 years of age who have impaired lung function because of LAM.\n\nDesign:\n\n* Participants will be screened with a physical exam and medical history. No lab tests will be needed for this study.\n* Participants will have a 3-day overnight stay at the National Institutes of Health. Those who are using long-acting inhalers will have to stop taking these drugs 1 week before the study.\n* Participants will receive either the nebulizer or two or four puffs of the inhaler. Four puffs of albuterol is a higher dose than is normally prescribed, and is being tested on this study.\n* Participants will have each treatment around the same time of day on each of the 3 days. Before and after taking the albuterol, participants will have lung function tests.",[28],[85,86,87,88],"Albuterol","Bronchodilator","Nebulizer","Metered Dose Inhaler","2026-06-13",{"date":91,"type":38},"2026-06-16",{"date":93,"type":38},"2013-06-10",{"date":95,"type":21},"2027-11-01",{"name":42,"class":43},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":74,"minAge":4,"maxAge":4,"enrollmentInfo":104,"targetDuration":106,"studyType":22,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":44},"100528403","tuberous-sclerosis-complex-and-lymphangioleiomyomatosis-pregnancy-registry-tsc-lam-registry-100528403","NCT06160310","Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)","Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry","Inclusion Criteria:\n\n* A pregnant woman with a clinical or genetic diagnosis of TSC as determined by the 2021 Consensus Guidelines (1)\n* A pregnant woman with a diagnosis of LAM\n* A pregnant woman with a variant of uncertain significance in TSC 1 or TSC 2\n* A pregnant woman who is pregnant and the fetus has a 50% chance of TSC as deemed by the PI or Sub-Is\n* A pregnant woman whose fetus is found to have concern for TSC secondary to rhabdomyomas, tubers, or congenital subependymal giant cell astrocytoma.\n* An infant born to an enrolled individual.\n\nExclusion Criteria:\n\n* A pregnant woman without TSC who has used preimplantation genetic testing for TSC unless qualifies under inclusion criteria #4.\n* Infants diagnosed with TSC whose birth mother was not enrolled.",{"count":105,"type":21},300,"5 Years","This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.",[109,28],"Tuberous Sclerosis Complex",[109,111,28,112],"TSC","LAM","2026-01-21",{"date":115,"type":38},"2026-01-23",{"date":117,"type":38},"2023-07-01",{"date":119,"type":21},"2029-07-01",{"name":121,"class":65},"David M. Ritter",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":74,"minAge":75,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":78,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100584425","phase-1-evaluating-the-long-term-safety-and-tolerability-of-imatinib-in-patients-with-lymphangioleiomyomatosis-lam-100584425","NCT06889168","Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)","A Phase 1, Randomized, Double-blinded, Placebo Controlled, Trial Evaluating the Long-term Safety and Tolerability of Imatinib for the Treatment of Lymphangioleiomyomatosis [LAMP-2 Trial]","LAMP-2","Inclusion Criteria:\n\n* Women 18 through 64 years of age (inclusive)\n* Pulmonary Function Test (PFT) with following criteria:\n\n  1. DLCO \\>20% predicted and FVC \\\u003C90% OR\n  2. Post bronchodilator FEV1 between 30% and 90% predicted.\n* Confirmed or possible diagnosis of LAM\n* Willing to avoid grapefruit juice and St. John's wort while in the study\n* Able and willing to comply with the study procedures\n\nExclusion Criteria:\n\n* Women who have or will undergo a transplant\n* Women who will undergo surgery\n* Women who are currently pregnant or plan on a pregnancy\n* Women who are currently breast feeding or lactating\n* Dementia or other cognitive dysfunction that, in the opinion of the investigator, would prevent the participant from consenting to the study or completing study procedures\n* Currently taking any of the following medications:\n\n  * Antifungal Medications: Ketoconazole; Itraconazole ; Voriconazole.\n  * Antibiotics for bacterial infections: Clarithromycin.\n  * Analgesics to treat headaches\u002Fmigraines: Dihydroergotamine; Dihydroergotamine intranasal\n  * Antiretroviral protease inhibitors used in human immunodeficiency virus (HIV) infections: Atazanavir ; Nelfinavir; Indinavir; Ritonavir; Saquinavir\n  * Anti-epileptic or seizure medications: Carbamazepine, Fosphenytoin; Oxcarbamazepine; Phenobarbital ; Phenytoin; Primidone\n  * Anti-depressant medications: Nefazodone; St. John's wort\n  * Targeted cancer drugs: Regorafenib; Venetoclax ; Cobimetinib\n  * Ivabradine (used to treat chronic heart failure); Telithromycin (used to treat community acquired pneumonia); Lomitapide (treatment of familial hypercholesterolemia); Lonafarnib (Hutchinson-Gilford progeria syndrome); conivaptan (treat low sodium levels); flibanserin (management of hypoactive sexual desire disorder (HSDD)); Naloxegol (opioid-induced constipation); Warfarin (prevent blood clots); Lurasidone (schizophrenia and bipolar depression); Eliglustat (treatment of Gaucher's disease).\n* Non English speaking, illiterate, or other vulnerable persons will not be included among study subjects.\n* Any condition that in the opinion of the investigator might adversely influence the study outcome.","64 Years",{"count":132,"type":21},20,[80],"Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease that appears to behave like a slowly growing cancer. Since clinical progression is very slow, new blood tests have been used to speed the time required to find safe and effective medications. A large National Institute of Health study called MILES showed that sirolimus (also known as Rapamycin) improved lung function in individuals with LAM. Since most individuals with LAM and impaired lung function are now on sirolimus, future studies may prove more difficult. Laboratory studies suggested that Imatinib mesylate (imatinib), an FDA-approved drug for leukemia, initiates LAM cell death. A pilot trial with imatinib titled \"Imatinib Mesylate for the treatment of Lymphangioleiomyomatosis\" - (LAMP-1) was funded by the Department of Defense in 2016, and documented (1) the safety of use of tyrosine kinase inhibitors in patients with LAM; (2) the safety of concurrent use of tyrosine kinase and mTOR inhibitors; and, (3) short term variability in vascular endothelial growth factor D (VEGF-D) - a LAM biomarker, as a response to therapies. Due to the short-term LAMP-1 trial, LAMP-2 will be a longer-term 6-month clinical study evaluating the safety and tolerability of imatinib in patients with LAM. Patients that participate in the trial will come in for 5 office visits and check-up phone calls every 2 weeks over the course of 6 months.",[136,28],"Lymphangioleiomyomatosis (LAM)",[112,128,138],"Imatinib","2026-01-19",{"date":113,"type":38},{"date":142,"type":38},"2025-10-20",{"date":144,"type":21},"2027-03",{"name":146,"class":65},"Columbia University",2,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":44},"100169823","national-lymphangioleiomyomatosis-registry-france-100169823","NCT01484236","National Lymphangioleiomyomatosis Registry, France","RE-LAM-CE","Inclusion Criteria:\n\n* Patients with sporadic lymphangioleiomyomatosis or associated with Tuberous sclerosis.\n* patients diagnosed or hospitalized or seen in consultation since 01\u002F01\u002F2008\n\nExclusion Criteria:\n\n* None",{"count":156,"type":21},200,"RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the timing and modalities of diagnosis.\n\nBased on the registry, we will set up a prospective cohort of patients. The database will include detailed medical information, particularly regarding progression of the respiratory function.",[28],[28],"2025-03-11",{"date":162,"type":38},"2025-03-13",{"date":164,"type":4},"2012-01",{"date":166,"type":21},"2026-12",{"name":168,"class":65},"Vincent COTTIN",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":74,"minAge":75,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":132},"100242305","safety-and-durability-of-sirolimus-for-treatment-of-lam-100242305","NCT02432560","Safety and Durability of Sirolimus for Treatment of LAM","Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)","MIDAS","Inclusion Criteria:\n\n* Female or male, age 18 or over\n* Diagnosis of LAM based on ATS\u002FJRS criteria\n* Signed and dated informed consent\n* On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy\n\nExclusion Criteria:\n\n* Inability to attend at least one RLD Clinic visit per year\n* Inability to give informed consent\n* Inability or unwillingness to perform pulmonary function testing",{"count":178,"type":21},600,"The MIDAS study aims to follow male and female LAM patients who are currently taking, have previously failed or been intolerant of, or may (at some time in the future) take mTOR inhibitors (sirolimus or everolimus) as part of their clinical care. Adult female TSC patients may also enroll, with or without lung cysts.",[28],[28,112,182,183],"rare lung","Rare Lung Disease","2024-12-18",{"date":186,"type":38},"2024-12-24",{"date":188,"type":38},"2015-03",{"date":190,"type":21},"2025-07-31",{"name":192,"class":65},"University of Cincinnati"]